Envestnet Asset Management
DNA icon

Envestnet Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Envestnet Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,166
Closed -$163K – 4247
2024
Q2 		$163K Sell
12,166
-9,937
-45% -$296K ﹤0.01% 3982
2024
Q1 		$1.03M Buy
22,103
+4,325
+24% +$224K ﹤0.01% 3014
2023
Q4 		$1.2M Buy
17,778
+8,857
+99% +$542K ﹤0.01% 2811
2023
Q3 		$646K Buy
8,921
+3,265
+58% +$261K ﹤0.01% 3107
2023
Q2 		$421K Buy
5,656
+2,862
+102% +$169K ﹤0.01% 3299
2023
Q1 		$149K Sell
2,794
-553
-17% -$35K ﹤0.01% 3727
2022
Q4 		$226K Buy
3,347
+26
+0.8% +$2.39K ﹤0.01% 3611
2022
Q3 		$414K Buy
3,321
+1,243
+60% +$148K ﹤0.01% 3131
2022
Q2 		$198K Buy
2,078
+767
+59% +$93.5K ﹤0.01% 3609
2022
Q1 		$211K Buy
+1,311
New +$255K ﹤0.01% 3657

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Envestnet Asset Management's DNA Position: Q3 2024 in Review

Envestnet Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 12,166 shares — an estimated $163K sold.

Envestnet Asset Management first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $1.2M in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Envestnet Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 12,166 Ginkgo Bioworks shares in Q3 2024, an estimated $163K.
  • Envestnet Asset Management first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Envestnet Asset Management's Ginkgo Bioworks position peaked at $1.2M in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Envestnet Asset Management's 13F filing for Q3 2024, filed 7 Nov 2024.